{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:27:34Z","timestamp":1791343654521,"version":"4.3.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2003,8,1]]},"DOI":"10.1038\/nrd1151","type":"journal-article","created":{"date-parts":[[2003,8,7]],"date-time":"2003-08-07T13:42:46Z","timestamp":1060263766000},"page":"624-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":164,"title":["Toxicity of antiretroviral therapy and implications for drug development"],"prefix":"10.1038","volume":"2","author":[{"given":"Andrew","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd1151_CR1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","volume":"356","author":"A Carr","year":"2000","unstructured":"Carr, A. & Cooper, D. A. Adverse effects of antiretroviral therapy. Lancet 356, 1423\u20131430 (2000).","journal-title":"Lancet"},{"key":"BFnrd1151_CR2","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","volume":"12","author":"K Brinkman","year":"1998","unstructured":"Brinkman, K., ter Hofstede, H. J., Burger, D. M., Smeitink, J. A. & Koopmans, P. P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12, 1735\u20131744 (1998).","journal-title":"AIDS"},{"key":"BFnrd1151_CR3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm0595-417","volume":"1","author":"W Lewis","year":"1995","unstructured":"Lewis, W. & Dalakas, M. C. Mitochondrial toxicity of antiviral drugs. Nature Med. 1, 417\u2013422 (1995).","journal-title":"Nature Med."},{"key":"BFnrd1151_CR4","unstructured":"US Food and Drug Administration. FDA\/Bristol Myers Squibb issues caution for HIV combination therapy with Zerit and Videx in pregnant women (FDA Talk Paper) [online] (cited 20 March 2003). <http:\/\/www.fda.gov\/bbs\/topics\/answers\/ans01063.html> (2001)."},{"key":"BFnrd1151_CR5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM200210173471623","volume":"347","author":"T Garcia-Benayas","year":"2002","unstructured":"Garcia-Benayas, T., Blanco, F. & Soriano, V. Weight loss in HIV-infected patients. N. Engl. J. Med. 347, 1287\u20131288 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1151_CR6","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/00002030-200009290-00011","volume":"14","author":"OT Rutschmann","year":"2000","unstructured":"Rutschmann, O. T. et al. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS 14, 2145\u20132151 (2000).","journal-title":"AIDS"},{"key":"BFnrd1151_CR7","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","volume":"14","author":"A Carr","year":"2000","unstructured":"Carr, A., Miller, J., Law, M. & Cooper, D. A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, F25\u201332 (2000).","journal-title":"AIDS"},{"key":"BFnrd1151_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200211010-00001","volume":"31","author":"M Schambelan","year":"2002","unstructured":"Schambelan, M. et al. Management of the metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Acquir. Immune Defic. Syndr. 31, 257\u2013275 (2002).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(00)04579-7","volume":"357","author":"A Carr","year":"2001","unstructured":"Carr, A., Morey, A., Mallon, P. W. G., Williams, D. & Thorburn, D. R. Fatal portal hypertension, chronic liver failure and persistent mitochondrial dysfunction after HIV nucleoside analogue-induced acute hepatitis and lactic acidaemia. Lancet 357, 1412\u20131414 (2001).","journal-title":"Lancet"},{"key":"BFnrd1151_CR10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(01)05910-4","volume":"358","author":"A Kronenberg","year":"2001","unstructured":"Kronenberg, A., Riehle, H. M. & Gunthard, H. F. Liver failure after long-term nucleoside antiretroviral therapy. Lancet 358, 759\u2013760 (2001).","journal-title":"Lancet"},{"key":"BFnrd1151_CR11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00002030-200104130-00007","volume":"15","author":"M John","year":"2001","unstructured":"John, M. et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15, 717\u2013723 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR12","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A Carr","year":"1998","unstructured":"Carr, A. et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51\u201358 (1998).","journal-title":"AIDS"},{"key":"BFnrd1151_CR13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(97)11518-5","volume":"351","author":"KD Miller","year":"1998","unstructured":"Miller, K. D. et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871\u2013875 (1998).","journal-title":"Lancet"},{"key":"BFnrd1151_CR14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(97)11443-X","volume":"351","author":"JC Lo","year":"1998","unstructured":"Lo, J. C., Mulligan, K., Tai, V. W., Algren, H. & Schambelan, M. 'Buffalo hump' in men with HIV-1 infection. Lancet 351, 867\u2013870 (1998).","journal-title":"Lancet"},{"key":"BFnrd1151_CR15","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0140-6736(05)64011-1","volume":"350","author":"RL Hengel","year":"1997","unstructured":"Hengel, R. L., Watts, N. B. & Lennox, J. L. Multiple symmetrical lipomatosis associated with protease inhibitors. Lancet 350, 1596 (1997).","journal-title":"Lancet"},{"key":"BFnrd1151_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1468-1293.2001.00071.x","volume":"2","author":"PWG Mallon","year":"2001","unstructured":"Mallon, P. W. G., Cooper, D. A. & Carr, A. HIV-associated lipodystrophy. HIV Med. 2, 166\u2013173 (2001).","journal-title":"HIV Med."},{"key":"BFnrd1151_CR17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A Carr","year":"1999","unstructured":"Carr, A. et al. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 353, 2093\u20132099 (1999).","journal-title":"Lancet"},{"key":"BFnrd1151_CR18","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1097\/00002030-199815000-00001","volume":"12","author":"R Walli","year":"1998","unstructured":"Walli, R. et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients. AIDS 12, F167\u2013174 (1998).","journal-title":"AIDS"},{"key":"BFnrd1151_CR19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00126334-199907010-00005","volume":"21","author":"KE Yarasheski","year":"1999","unstructured":"Yarasheski, K. E. et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J. Acquir. Immune Defic. Syndr. 21, 209\u2013216 (1999).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","volume":"32","author":"C Hadigan","year":"2001","unstructured":"Hadigan, C. et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32, 130\u2013139 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd1151_CR21","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","volume":"16","author":"V Joly","year":"2002","unstructured":"Joly, V. et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 16, 2447\u20132454 (2002).","journal-title":"AIDS"},{"key":"BFnrd1151_CR22","unstructured":"Staszewski, S. et al. in Abstracts of the 14th International AIDS Conference. 7\u201312 July 2002, Barcelona, Spain. Abstract LBOr17."},{"key":"BFnrd1151_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","volume":"288","author":"A Carr","year":"2002","unstructured":"Carr, A. et al. for the MITOX investigators. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288, 207\u2013215 (2002).","journal-title":"JAMA"},{"key":"BFnrd1151_CR24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","volume":"15","author":"KA Lichtenstein","year":"2001","unstructured":"Lichtenstein, K. A. et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15, 1389\u20131398 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00126334-200209010-00007","volume":"31","author":"E Bernasconi","year":"2002","unstructured":"Bernasconi, E. et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr. 31, 50\u201355 (2002).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002030-200101260-00013","volume":"15","author":"K Heath","year":"2001","unstructured":"Heath, K. et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database. AIDS 15, 231\u2013240 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","volume":"357","author":"E Martinez","year":"2001","unstructured":"Martinez, E. et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357, 592\u2013598 (2001).","journal-title":"Lancet"},{"key":"BFnrd1151_CR28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00042560-200208010-00010","volume":"30","author":"KV Heath","year":"2002","unstructured":"Heath, K. V. et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J. Acquir. Immune Defic. Syndr. 30, 440\u2013447 (2002).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","volume":"361","author":"A Carr","year":"2003","unstructured":"Carr A. et al. An objective case definition of lipodystrophy in HIV-infected adults. Lancet 361, 726\u2013735 (2003).","journal-title":"Lancet"},{"key":"BFnrd1151_CR30","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","volume":"351","author":"A Carr","year":"1998","unstructured":"Carr, A., Samaras, K., Chisholm, D. J. & Cooper, D. A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351, 1881\u20131883 (1998).","journal-title":"Lancet"},{"key":"BFnrd1151_CR31","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1210\/jcem.84.11.6234","volume":"84","author":"B Zhang","year":"1999","unstructured":"Zhang, B. et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J. Clin. Endocrinol. Metab. 84, 4274\u20134277 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrd1151_CR32","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","volume":"50","author":"M Caron","year":"2001","unstructured":"Caron, M. et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50, 1378\u20131388 (2001).","journal-title":"Diabetes"},{"key":"BFnrd1151_CR33","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1677\/joe.0.164r007","volume":"164","author":"JM Wentworth","year":"2000","unstructured":"Wentworth, J. M., Burris, T. P. & Chatterjee, V. K. K. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPAR\u03b3\/RXR heterodimer. J. Endocrinol. 164, R7\u201310 (2000).","journal-title":"J. Endocrinol."},{"key":"BFnrd1151_CR34","doi-asserted-by":"crossref","first-page":"41325","DOI":"10.1074\/jbc.M006474200","volume":"275","author":"P Dowell","year":"2000","unstructured":"Dowell, P., Flexner, C., Kwiterovich, P. O. & Lane, M. D. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J. Biol. Chem. 275, 41325\u201341332 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1151_CR35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0140-6736(02)08094-7","volume":"359","author":"JP Bastard","year":"2002","unstructured":"Bastard, J. P. et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359, 1026\u20131031 (2002).","journal-title":"Lancet"},{"key":"BFnrd1151_CR36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00042560-200202010-00002","volume":"29","author":"UA Walker","year":"2002","unstructured":"Walker, U. A. et al. Evidence of nucleoside analogue reverse transcriptase inhibitor\u2014associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J. Acquir. Immune Defic. Syndr. 29, 117\u2013121 (2002).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR37","unstructured":"Janneh, O. et al. in Program and Abstracts of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. 22\u201325 September 2002, San Diego, USA. Abstract 2."},{"key":"BFnrd1151_CR38","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/00002030-200109280-00009","volume":"15","author":"CM Shikuma","year":"2001","unstructured":"Shikuma, C. M. et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV infected individuals with peripheral lipoatrophy. AIDS 15, 1801\u20131809 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR39","first-page":"516","volume":"297","author":"I Gaou","year":"2001","unstructured":"Gaou, I. et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J. Pharmacol. Exp. Ther. 297, 516\u2013523 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd1151_CR40","unstructured":"Boyd, M. et al. in Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. 10\u201314 February 2003, Boston, USA. Abstract 738."},{"key":"BFnrd1151_CR41","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","volume":"15","author":"A Carr","year":"2001","unstructured":"Carr, A. et al. for the PIILR investigators. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, multicentre, open-label study. AIDS 15, 1811\u20131822 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00126334-200107010-00003","volume":"27","author":"L Ruiz","year":"2001","unstructured":"Ruiz, L. et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J. Acquir. Immune Defic. Syndr. 27, 229\u2013233 (2001).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR43","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","volume":"15","author":"S Duran","year":"2001","unstructured":"Duran, S. et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 15, 2441\u20132444 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","volume":"28","author":"A Ammassari","year":"2001","unstructured":"Ammassari, A. et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 28, 445\u2013449 (2001).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9343(02)01156-7","volume":"113","author":"LA Lenert","year":"2002","unstructured":"Lenert, L. A., Feddersen, M., Sturley, A. & Lee, D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am. J. Med. 113, 229\u2013232 (2002).","journal-title":"Am. J. Med."},{"key":"BFnrd1151_CR46","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","volume":"17","author":"N Friis-M\u00f8ller","year":"2003","unstructured":"Friis-M\u00f8ller, N. et al. Cardiovascular risk factors in HIV patients: association with antiretroviral therapy. AIDS 17, 1179\u20131193 (2003).","journal-title":"AIDS"},{"key":"BFnrd1151_CR47","first-page":"1045","volume":"74","author":"C Grunfeld","year":"1992","unstructured":"Grunfeld, C. et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Clin. Endocrinol. Metab. 74, 1045\u20131052 (1992).","journal-title":"Clin. Endocrinol. Metab."},{"key":"BFnrd1151_CR48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","volume":"14","author":"J Purnell","year":"2000","unstructured":"Purnell, J. et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14, 51\u201357 (2000).","journal-title":"AIDS"},{"key":"BFnrd1151_CR49","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/00002030-200105040-00001","volume":"15","author":"MA Noor","year":"2001","unstructured":"Noor, M. A. et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15, F11\u201318 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR50","unstructured":"Lee, G. A. et al. in Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. 10\u201314 February 2003, Boston, USA. Abstract 748."},{"key":"BFnrd1151_CR51","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm1201-1327","volume":"7","author":"JS Liang","year":"2001","unstructured":"Liang, J. S. et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Med. 7, 1327\u20131331 (2001).","journal-title":"Nature Med."},{"key":"BFnrd1151_CR52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00041433-200106000-00011","volume":"12","author":"V Mooser","year":"2001","unstructured":"Mooser, V. & Carr, A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr. Opin. Lipidol. 12, 313\u2013319 (2001).","journal-title":"Curr. Opin. Lipidol."},{"key":"BFnrd1151_CR53","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1097\/00002030-200110190-00020","volume":"15","author":"AR Miserez","year":"2001","unstructured":"Miserez, A. R. et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 15, 2045\u20132049 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","volume":"108","author":"A Garg","year":"2000","unstructured":"Garg, A. Lipodystrophies. Am. J. Med. 108, 143\u2013152 (2000).","journal-title":"Am. J. Med."},{"key":"BFnrd1151_CR55","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-200112070-00008","volume":"15","author":"M van der Valk","year":"2001","unstructured":"van der Valk, M. et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15, 2407\u20132414 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR56","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","volume":"275","author":"H Murata","year":"2000","unstructured":"Murata, H., Hruz, P. W. & Mueckler, M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275, 20251\u201320254 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1151_CR57","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2337\/diabetes.50.6.1397","volume":"50","author":"LA Nolte","year":"2001","unstructured":"Nolte, L. A. et al. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 50, 1397\u20131401 (2001).","journal-title":"Diabetes"},{"key":"BFnrd1151_CR58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2337\/diab.45.5.633","volume":"45","author":"DG Carey","year":"1996","unstructured":"Carey, D. G., Jenkins, A. B., Campbell, L. V., Freund, J. & Chisholm, D. J. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45, 633\u2013638 (1996).","journal-title":"Diabetes"},{"key":"BFnrd1151_CR59","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2337\/diabetes.51.11.3163","volume":"51","author":"SK Gan","year":"2002","unstructured":"Gan, S. K. et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 51, 3163\u20133169 (2002).","journal-title":"Diabetes"},{"key":"BFnrd1151_CR60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00002030-200102160-00005","volume":"15","author":"M Depairon","year":"2001","unstructured":"Depairon, M. et al. Premature atherosclerosis in HIV-infected individuals \u2014 focus on protease inhibitor therapy. AIDS 15, 329\u2013334 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/078538902317338652","volume":"34","author":"P Mercie","year":"2002","unstructured":"Mercie, P. et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann. Med. 34, 55\u201363 (2002).","journal-title":"Ann. Med."},{"key":"BFnrd1151_CR62","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","volume":"348","author":"SA Bozzette","year":"2003","unstructured":"Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W. & Louis, T. A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348, 702\u2013710 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1151_CR63","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(02)11672-2","volume":"360","author":"SD Holmberg","year":"2002","unstructured":"Holmberg, S. D. et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360, 1747\u20131748 (2002).","journal-title":"Lancet"},{"key":"BFnrd1151_CR64","unstructured":"Mary-Krause, M., Cotte, L., Partisani, M., Simon, A. & Costagliola, D. in Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. 4\u20138 February 2001, Chicago, USA. Abstract 657."},{"key":"BFnrd1151_CR65","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00126334-200308010-00012","volume":"33","author":"JS Currier","year":"2003","unstructured":"Currier, J. S. et al. Coronary heart disease in HIV\u2013infected individuals. J. Acquir. Immune Defic. Syndr. 33, 506\u2013512 (2003).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR66","unstructured":"Friis-M\u00f8ller, N. et al. in Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. 10\u201314 February, 2003. Boston, USA. Abstract 130."},{"key":"BFnrd1151_CR67","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","volume":"328","author":"SA Coopman","year":"1993","unstructured":"Coopman, S. A., Johnson, R. A., Platt, R. & Stern, R. S. Cutaneous disease and drug reactions in HIV infection. N. Engl. J. Med. 328, 1670\u20131674 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1151_CR68","unstructured":"FDA Drug Approvals List [online] (cited 6 Jun 2003) <http:\/\/www.fda.gov\/cder\/foi\/label\/2002\/20636slr016,20933slr006_viramune_lbl.pdf> (2002)."},{"key":"BFnrd1151_CR69","unstructured":"Severe nevirapine rash found more likely in women than men. Treatment Update 12, 7 (2001)."},{"key":"BFnrd1151_CR70","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2249.1994.tb06078.x","volume":"97","author":"A Carr","year":"1994","unstructured":"Carr, A., Vasak, E., Munro, V., Penny, R. & Cooper, D. A. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin. Exp. Immunol. 97, 260\u2013265 (1994).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrd1151_CR71","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727\u2013732 (2002).","journal-title":"Lancet"},{"key":"BFnrd1151_CR72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","volume":"186","author":"FW Wit","year":"2002","unstructured":"Wit, F. W., Weverling, G. J., Weel, J., Jurriaans, S. & Lange, J. M. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J. Infect. Dis. 186, 23\u201331 (2002).","journal-title":"J. Infect. Dis."},{"key":"BFnrd1151_CR73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski, M. S., Thomas, D. L., Chaisson, R. E. & Moore, R. D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283, 74\u201380 (2000).","journal-title":"JAMA"},{"key":"BFnrd1151_CR74","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1097\/00002030-200012220-00011","volume":"14","author":"M den Brinker","year":"2000","unstructured":"den Brinker, M. et al. Hepatitis B and C co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14, 2895\u20132902 (2000).","journal-title":"AIDS"},{"key":"BFnrd1151_CR75","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/AAC.44.12.3451-3455.2000","volume":"44","author":"M Saves","year":"2000","unstructured":"Saves, M. et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 44, 3451\u20133455 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd1151_CR76","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/317449","volume":"31","author":"EH Gisolf","year":"2000","unstructured":"Gisolf, E. H., Dreezen, C., Danner, S. A., Weel, J. L. & Weverling, G. J. Risk factors for hepatotoxicity in HIV-1 infected patients receiving ritonavir and saquinavir with or without stavudine. Clin. Infect. Dis. 31, 1234\u20131239 (2000).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd1151_CR77","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","volume":"15","author":"E Martinez","year":"2001","unstructured":"Martinez, E. et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15, 1261\u20131268 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR78","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/095646240001100511","volume":"11","author":"S Clarke","year":"2000","unstructured":"Clarke, S. et al. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int. J. STD AIDS 11, 336\u2013337 (2000).","journal-title":"Int. J. STD AIDS"},{"key":"BFnrd1151_CR79","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/00002030-199817000-00010","volume":"12","author":"M John","year":"1998","unstructured":"John, M., Flexham, J. & French, M. A. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12, 2289\u20132293 (1998).","journal-title":"AIDS"},{"key":"BFnrd1151_CR80","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(05)62892-9","volume":"349","author":"A Carr","year":"1997","unstructured":"Carr, A. & Cooper, D. A. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349, 995\u2013996 (1997).","journal-title":"Lancet"},{"key":"BFnrd1151_CR81","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(97)04352-3","volume":"351","author":"EM Race","year":"1998","unstructured":"Race, E. M. et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351, 252\u2013255 (1998).","journal-title":"Lancet"},{"key":"BFnrd1151_CR82","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(98)80017-2","volume":"29","author":"M Altfeld","year":"1998","unstructured":"Altfeld, M. et al. Reaction of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J. Hepatol. 29, 306\u2013309 (1998).","journal-title":"J. Hepatol."},{"key":"BFnrd1151_CR83","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","volume":"30","author":"Y Benhamou","year":"1999","unstructured":"Benhamou, Y. et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30, 1302\u20131306 (1999).","journal-title":"Hepatology"},{"key":"BFnrd1151_CR84","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/514750","volume":"28","author":"M Bessesen","year":"1999","unstructured":"Bessesen, M., Ives, D., Condreay, L., Lawrence, S. & Sherman, K. E. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin. Infect. Dis. 28, 1032\u20131035 (1999).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd1151_CR85","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1086\/317535","volume":"32","author":"C Manegold","year":"2001","unstructured":"Manegold, C. et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 32, 144\u2013148 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd1151_CR86","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00002030-200006160-00007","volume":"14","author":"D Pillay","year":"2000","unstructured":"Pillay, D., Cane, P. A., Ratcliffe, D., Atkins, M. & Cooper, D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. AIDS 14, 1111\u20131116 (2000).","journal-title":"AIDS"},{"key":"BFnrd1151_CR87","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 691\u2013698 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1151_CR88","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00002030-200302140-00026","volume":"17","author":"HD Poulsen","year":"2003","unstructured":"Poulsen, H. D. & Lublin, H. K. Efavirenz-induced psychosis leading to involuntary detention. AIDS 17, 451\u2013453 (2003).","journal-title":"AIDS"},{"key":"BFnrd1151_CR89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini, C. et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71\u201375 (2001).","journal-title":"AIDS"},{"key":"BFnrd1151_CR90","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00126334-200108010-00003","volume":"27","author":"J Blanch","year":"2001","unstructured":"Blanch, J. et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J. Acquir. Immune Defic. Syndr. 27, 336\u2013343 (2001).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrd1151_CR91","unstructured":"US Department of Health and Human Services Food and Drug Administration. Report to the FDA commissioner from the task force on risk management. Managing the risk from medical product use. Creating a risk management framework (1999)."},{"key":"BFnrd1151_CR92","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0140-6736(01)06413-3","volume":"358","author":"J Fellay","year":"2001","unstructured":"Fellay, J. et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 1322\u20131327 (2001).","journal-title":"Lancet"},{"key":"BFnrd1151_CR93","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/322590","volume":"33","author":"J McNabb","year":"2001","unstructured":"McNabb, J. et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin. Infect. Dis. 33, 700\u2013705 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd1151_CR94","doi-asserted-by":"crossref","unstructured":"Carrieri, P. et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French national APROCO cohort. J. Acquir. Immune Defic. Syndr. 28, 232\u2013239.","DOI":"10.1097\/00042560-200111010-00005"},{"key":"BFnrd1151_CR95","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(02)09341-8","volume":"360","author":"A Carr","year":"2002","unstructured":"Carr, A. Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet 360, 81\u201385 (2002).","journal-title":"Lancet"},{"key":"BFnrd1151_CR96","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jama.285.4.437","volume":"285","author":"JPA Ioannidis","year":"2001","unstructured":"Ioannidis, J. P. A. & Lau, J. Completeness of safety reporting in randomised trials: an evaluation of 7 medical areas. JAMA 285, 437\u2013443 (2001).","journal-title":"JAMA"},{"key":"BFnrd1151_CR97","unstructured":"US Department of Health and Human Services Food and Drug Administration. Guidance for Industry. S7A safety pharmacology studies for human pharmaceuticals. [online] (cited 6 August 2001). <http:\/\/www.fda.gov\/cder\/guidance\/index.htm> (2001)."},{"key":"BFnrd1151_CR98","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/00002030-200007070-00019","volume":"14","author":"AW Wu","year":"2000","unstructured":"Wu, A. W. Quality of life assessment comes of age in the era of highly active antiretroviral therapy. AIDS 14, 1449\u20131451 (2000).","journal-title":"AIDS"},{"key":"BFnrd1151_CR99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1468-1293.2001.00045.x","volume":"2","author":"O Kirk","year":"2001","unstructured":"Kirk, O. et al. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med. 2, 43\u201351 (2001).","journal-title":"HIV Med."},{"key":"BFnrd1151_CR100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0753-3322(01)00070-1","volume":"55","author":"P Bonfanti","year":"2001","unstructured":"Bonfanti, P. et al. Predictors of protease inhibitor-associated adverse events. Biomed. Pharmacother. 55, 321\u2013323 (2001).","journal-title":"Biomed. Pharmacother."},{"key":"BFnrd1151_CR101","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/00002030-200006160-00014","volume":"14","author":"A Carr","year":"2000","unstructured":"Carr, A. et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 14, 1171\u20131180 (2000).","journal-title":"AIDS"},{"key":"BFnrd1151_CR102","unstructured":"European Agency for the Evaluation of Medicinal Products. Note for guidance on structure and content of clinical study reports (CPMP\/ICP\/137\/95). ICH Topic E3. Structure and content of clinical study reports. Step 4, consensus guidelines (1995)."},{"key":"BFnrd1151_CR103","unstructured":"European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. ICH Topic E9. Statistical principals for clinical trials (CPMP\/ICH\/363\/96). [online] (cited 6 August 2001) <http:\/\/www.emea.eu.int\/> (2001)."},{"key":"BFnrd1151_CR104","unstructured":"European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use. ICH M4E. Common technical document for the registration of pharmaceuticals for human use \u2014 efficacy (CPMP\/ICH\/2887 Efficacy). [online] (cited 6 August 2001) <http:\/\/www.emea.eu.int\/> (2001)."},{"key":"BFnrd1151_CR105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","volume":"134","author":"DG Altman","year":"2001","unstructured":"Altman, D. G. et al. for the CONSORT Group. The revised CONSORT statement for reporting randomised trials: explanation and elaboration. Ann. Intern. Med. 134, 663\u2013694 (2001).","journal-title":"Ann. Intern. Med."},{"key":"BFnrd1151_CR106","doi-asserted-by":"crossref","unstructured":"International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N. Engl. J. Med. 336, 309\u2013315 (1997).","DOI":"10.1056\/NEJM199701233360422"},{"key":"BFnrd1151_CR107","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-200363080-00002","volume":"63","author":"R Aarnoutse","year":"2003","unstructured":"Aarnoutse, R., Schapiro, J., Boucher, C., Hekster, Y. & Burger, D. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 63, 741\u2013753 (2003).","journal-title":"Drugs"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrd1151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd1151","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd1151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:48:38Z","timestamp":1659174518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd1151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":107,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8,1]]}},"alternative-id":["BFnrd1151"],"URL":"https:\/\/doi.org\/10.1038\/nrd1151","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}